Korean J Helicobacter Up Gastrointest Res.
2022 Sep;22(3):243-245. 10.7704/kjhugr.2022.0025.
Efficacy of Bismuth-based Quadruple Therapy as First-line Treatment for Clarithromycin-resistant Helicobacter pylori Infection
- Affiliations
-
- 1Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea
- 2Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Korea
- KMID: 2533119
- DOI: http://doi.org/10.7704/kjhugr.2022.0025
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Recent Trends of Helicobacter pylori Eradication Therapy: Focusing on First Line Treatment
- Management of Helicobacter pylori Infection in Europe: Focusing on the Maastricht V/Florence Consensus
- Bismuth-Based Quadruple Therapy versus MetronidazoleIntensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Multicenter Randomized Controlled Trial
- Current Trends of Helicobacter pylori Eradication in Korea
- Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Prospective Randomized Comparison of 7- and 14-Day Treatment Regimens
